Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
Basal cell carcinoma (BCC) is the most common skin cancer. It generally has an indolent course with low rates of metastasis and mortality. However, BCC is locally invasive and can cause significant morbidity due to destructive local spread. We report our experience with a patient who was referred to...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of São Paulo
2019-10-01
|
| Series: | Autopsy and Case Reports |
| Subjects: | |
| Online Access: | http://www.revistas.usp.br/autopsy/article/view/162876 |
| _version_ | 1818148710613254144 |
|---|---|
| author | Pedro Carvalho Martins Rita Valença Filipe Rui Barbosa Ivo Julião Rosa Azevedo Matilde Ribeiro Abreu de Sousa |
| author_facet | Pedro Carvalho Martins Rita Valença Filipe Rui Barbosa Ivo Julião Rosa Azevedo Matilde Ribeiro Abreu de Sousa |
| author_sort | Pedro Carvalho Martins |
| collection | DOAJ |
| description | Basal cell carcinoma (BCC) is the most common skin cancer. It generally has an indolent course with low rates of metastasis and mortality. However, BCC is locally invasive and can cause significant morbidity due to destructive local spread. We report our experience with a patient who was referred to our skin cancer unit due to a previously neglected lesion on the parietal region of the scalp, which had developed for 7 years. The patient was prescribed vismodegib on the basis that surgery could cause excessive functional and aesthetic damage. The patient had an objective partial response after 20 months of treatment. He was then submitted to radical skin excision, leaving a large defect that was reconstructed using a free latissimus dorsi muscle flap. The patient recovered well, and at the 1-year follow-up there were no signs of local recurrence. Our case demonstrates the value of vismodegib treatment prior to surgery in a locally advanced, high-risk scalp BCC and highlights the importance of an individualized and specialized approach with these patients, within a multidisciplinary team |
| first_indexed | 2024-12-11T12:55:28Z |
| format | Article |
| id | doaj.art-045a2c4174564cb58e1857c452b56b16 |
| institution | Directory Open Access Journal |
| issn | 2236-1960 |
| language | English |
| last_indexed | 2024-12-11T12:55:28Z |
| publishDate | 2019-10-01 |
| publisher | University of São Paulo |
| record_format | Article |
| series | Autopsy and Case Reports |
| spelling | doaj.art-045a2c4174564cb58e1857c452b56b162022-12-22T01:06:35ZengUniversity of São PauloAutopsy and Case Reports2236-19602019-10-019410.4322/acr.2019.116Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegibPedro Carvalho Martins0Rita Valença Filipe1Rui Barbosa2Ivo Julião3Rosa Azevedo4Matilde Ribeiro5Abreu de Sousa6Instituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial, Surgical Oncology ServiceInstituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial, Reconstructive and Plastic Surgery Servicenstituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial, Reconstructive and Plastic Surgery Servicenstituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial, Medical Oncology ServiceInstituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial, Pathological Anatomy ServiceInstituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial, Reconstructive and Plastic Surgery ServiceInstituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial, Surgical Oncology ServiceBasal cell carcinoma (BCC) is the most common skin cancer. It generally has an indolent course with low rates of metastasis and mortality. However, BCC is locally invasive and can cause significant morbidity due to destructive local spread. We report our experience with a patient who was referred to our skin cancer unit due to a previously neglected lesion on the parietal region of the scalp, which had developed for 7 years. The patient was prescribed vismodegib on the basis that surgery could cause excessive functional and aesthetic damage. The patient had an objective partial response after 20 months of treatment. He was then submitted to radical skin excision, leaving a large defect that was reconstructed using a free latissimus dorsi muscle flap. The patient recovered well, and at the 1-year follow-up there were no signs of local recurrence. Our case demonstrates the value of vismodegib treatment prior to surgery in a locally advanced, high-risk scalp BCC and highlights the importance of an individualized and specialized approach with these patients, within a multidisciplinary teamhttp://www.revistas.usp.br/autopsy/article/view/162876CarcinomaBasal CellInterdisciplinary ResearchNeoadjuvant TherapyReconstructive Surgical Procedures |
| spellingShingle | Pedro Carvalho Martins Rita Valença Filipe Rui Barbosa Ivo Julião Rosa Azevedo Matilde Ribeiro Abreu de Sousa Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib Autopsy and Case Reports Carcinoma Basal Cell Interdisciplinary Research Neoadjuvant Therapy Reconstructive Surgical Procedures |
| title | Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib |
| title_full | Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib |
| title_fullStr | Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib |
| title_full_unstemmed | Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib |
| title_short | Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib |
| title_sort | basal cell carcinoma multimodal treatment and the role of neoadjuvant vismodegib |
| topic | Carcinoma Basal Cell Interdisciplinary Research Neoadjuvant Therapy Reconstructive Surgical Procedures |
| url | http://www.revistas.usp.br/autopsy/article/view/162876 |
| work_keys_str_mv | AT pedrocarvalhomartins basalcellcarcinomamultimodaltreatmentandtheroleofneoadjuvantvismodegib AT ritavalencafilipe basalcellcarcinomamultimodaltreatmentandtheroleofneoadjuvantvismodegib AT ruibarbosa basalcellcarcinomamultimodaltreatmentandtheroleofneoadjuvantvismodegib AT ivojuliao basalcellcarcinomamultimodaltreatmentandtheroleofneoadjuvantvismodegib AT rosaazevedo basalcellcarcinomamultimodaltreatmentandtheroleofneoadjuvantvismodegib AT matilderibeiro basalcellcarcinomamultimodaltreatmentandtheroleofneoadjuvantvismodegib AT abreudesousa basalcellcarcinomamultimodaltreatmentandtheroleofneoadjuvantvismodegib |